The ADJUVANT/CTONG1104 study concluded that adjuvant gefitinib led to longer DFS compared with that for vinorelbine plus cisplatin in patients with completely resected stage II–IIIA EGFR‐mutated NSCLC (HR: 0.60; 95% CI: 0.42–0.97).22 Here, EGFR is linked to non-small cell lung carcinoma.